Literature DB >> 21333373

Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.

Neil Boudville1, Rohan Paul, Bruce W S Robinson, Jenette Creaney.   

Abstract

PURPOSE: Malignant mesothelioma (MM) carries a poor prognosis and remains a major public health issue in many countries. Outcomes may be improved with earlier detection and this justifies screening the at-risk asbestos-exposed population. Soluble mesothelin is a potential biomarker for MM, but it has been observed to be elevated in patients with reduced kidney function. Defining the relationship between mesothelin concentrations and kidney function will allow more accurate interpretation of this assay.
MATERIALS AND METHODS: A cross-sectional study consisting of 144 patients with chronic kidney disease (CKD) was conducted at Sir Charles Gairdner Hospital and Royal Perth Hospital in Western Australia. Only patients with CKD stages II-V were recruited while those with a history of renal transplant, dialysis, or malignancy were excluded. Serum and urine mesothelin and creatinine concentrations were determined.
RESULTS: There were 33, 49, 31 and 31 patients in CKD stages II, III, IV and V, respectively recruited. Serum mesothelin increased significantly with increasing serum creatinine (p<0.0001), and worsening stage of CKD (p<0.0001). A significant correlation between urine mesothelin to creatinine ratio and serum mesothelin concentration was detected (p=0.002). No significant difference was found in urine mesothelin to creatinine ratios across the four CKD stage groups.
CONCLUSION: Serum mesothelin concentration is elevated in individuals with renal impairment. Renal function should therefore be taken into account during interpretation of this assay.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333373     DOI: 10.1016/j.lungcan.2011.01.011

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

Review 1.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Authors:  Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 4.  Biomarkers in the prevention and follow-up of workers exposed to asbestos.

Authors:  Rudy Foddis; Alessandra Bonotti; Stefano Landi; Poupak Fallahi; Giovanni Guglielmi; Alfonso Cristaudo
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.

Authors:  Jenette Creaney; Amanda Segal; Nola Olsen; Ian M Dick; A W Bill Musk; Steven J Skates; Bruce W Robinson
Journal:  Dis Markers       Date:  2014-11-23       Impact factor: 3.434

6.  Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.

Authors:  Ruiyue Gao; Feng Wang; Zhen Wang; Yanbing Wu; Lili Xu; Yue Qin; Huanzhong Shi; Zhaohui Tong
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.

Authors:  Jenette Creaney; Sophie Sneddon; Ian M Dick; Hanne Dare; Neil Boudville; Arthur William Musk; Steven J Skates; Bruce W S Robinson
Journal:  Dis Markers       Date:  2013-08-06       Impact factor: 3.434

8.  A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.

Authors:  Mark Linch; Spyridon Gennatas; Stanislav Kazikin; Jhangir Iqbal; Ranga Gunapala; Kathryn Priest; Joanne Severn; Alison Norton; Bee Ayite; Jaishree Bhosle; Mary O'Brien; Sanjay Popat
Journal:  BMC Cancer       Date:  2014-09-17       Impact factor: 4.430

9.  Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.

Authors:  Elizabeth B Somers; Daniel J O'Shannessy
Journal:  Biomark Insights       Date:  2014-05-25

10.  Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Authors:  Georg Johnen; Katarzyna Burek; Irina Raiko; Katharina Wichert; Beate Pesch; Daniel G Weber; Martin Lehnert; Swaantje Casjens; Olaf Hagemeyer; Dirk Taeger; Thomas Brüning
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.